Barclays Maintains Overweight on Oruka Therapeutics, Raises Price Target to $78

Oruka Therapeutics

Oruka Therapeutics

ORKA

0.00

Barclays analyst Etzer Darout maintains Oruka Therapeutics (NASDAQ: ORKA) with a Overweight and raises the price target from $50 to $78.